Zentalis pharmaceuticals inc ZNTL.US Value Analysis
US StockHealth Care
(No presentation for ZNTL)
ZNTL Value Score
3
24
15
Limited Growth
- AI analysis rates ZNTL with a lower value score of 2.
- It is mainly due to unstable operating cash flow, along with potential value may be lower.
- Over the past 3 months, ZNTL has maintained a consecutive value rating of 2.0, slightly higher than the rating of 0.9 over the past 3 years. However, growth opportunities for enterprise value remain relatively low.
- Compared to all stocks in the Health Care sector, ZNTL has a medium value rating.
ZNTL Value Reference Factors
The Value score is derived from various data and factor information, integrated through AI algorithms. The following factors are part of the evaluation used by AI value scores.
Update to 2025/04/12 (Weekly Update)
ZNTL Financial Forecast
Unit : USD
Update to 2025/5/4 (Quarterly Update)
ZNTL Earnings Table
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | 0.14 | - | -118.2% | 40.56M | - | 209.1% | -2,895.3% |
Update to 2025/5/8 (Quarterly Update)
ZNTL Historical Value Score
You can use historical scores of 3 or above to observe potential performance and make investment decisions.
ZNTL Value Strategy Backtest
The following backtest is based on specified rules since 2007. Price chart shows buy/sell time, cumulative returns, and backtesting statistics.
Entry
Exit
The Backtest Result of ZNTL from 2020/04 till Now
- -
- Cumulative Return
- -
- Annual Return
- -
- Volatility
- -
- Sharpe Ratio
Statistics data for entering at or above a Value score of 4 and exiting at or below a Value score of 2 from April, 2020 to May, 2025. (Total Trades: 0)
| ZNTL | Sector | US Overall Market | |
|---|---|---|---|
| Wining Rate | - | 44% | 53% |
| Avg Return | - | 63.1% | 72.3% |
| Avg Profit | - | 198.4% | 166.4% |
| Avg Loss | - | -44.8% | -34.6% |
| Avg Risk-Reward Ratio | - | 442.5% | 480.4% |
Update to 2025/5/8 (Daily Update)